The Federal Circuit Bar Association (FCBA) will be offering a remote program entitled "Bio Pharma: Current Trends in Written Description and Enablement, and Employee Mobility" on September 22, 2021 from 11:00 am to 1:45 pm (ET).  The program will consist of two panels:

• Panel I — Current Topics in the Federal Circuit’s Law of Written Description and Enablement — John Josef Molenda of Steptoe & Johnson LLP will moderate a panel consisting of Larry Coury of Regeneron Pharmaceuticals, Inc.; Henry Hadad of Bristol-Myers Squibb; Joshua Rosenkranz of Orrick, Herrington & Sutcliffe LLP; and John Whealan of The George Washington Law School. The panel will discuss current topics in the Federal Circuit's law of written description and enablement, with a focus on recent Federal Circuit decisions and their impact on the biopharma industry.

• Panel II — Practical Effects of Recent Caselaw on Employee Mobility in Biotech — John A. Dragseth of Fish & Richardson PC will moderate a panel consisting of Gregory A. Castanias of Jones Day, Nitika Gupta Fiorella of Fish & Richardson PC, and Jennifer Sklenar of Arnold & Porter Kaye Scholer LLP.  The panel will discuss recent decisions on patent inventorship, ownership, and related areas, including the Supreme Court's Minerva v. Hologic decision; consider practical implications of those decisions for litigators, prosecutors, in-house counsel, and management; and will consider how those considerations interact with trends in the technology employment landscape.

The webinar is complimentary for FCBA members, judges, and students, $75 for government/academic/retired attendees, $150 for young lawyers (age 24 or younger) and small firm practitioners (less than 25 attorneys), and $300 for private practitioners.  Those interested in registering for the program, can do so here.